Skip to content

Microbot Medical MBOT Deferred Tax Assets Advance Payment From Iia

Deferred Tax Assets Advance Payment From Iia at other companies

Nano Nuclear Energy logo
Nano Nuclear EnergyNNE
$309.09K
SB Financial Group logo
SB Financial GroupSBFG
$102K+13.3%
NioCorp Developments Ltd. logo
NioCorp Developments Ltd.NB
$1.3M-8.7%
Venu Holding logo
Venu HoldingVENU
$338.39K-17.0%
Falcon's Beyond Global logo
Falcon's Beyond GlobalFBYD
-$1.2M+7.8%
Dutch Bros logo
Dutch BrosBROS
$943.4M+1.4%

Other financials

Income statement

See full
Revenue$105.0K
Gross profit$2.0K
Operating income-$4.3M-43.0%
Net income-$3.7M-41.1%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$3.7M+13.7%
Total debt$898.0K+551%
Total equity$74.1M+156%
Total assets$78.1M+153%

Cash flow

See full
Operating cash flow-$5.1M-75.8%
CapEx$108.0K+731%
Free cash flow-$5.2M-78.8%

Valuation

See full
Market cap$128.28M+36.1%
Enterprise value$125.53M+39.0%
P/S674.3×

Profitability

See full
Operating margin25,292.9%
Net margin-3,669.9%
FCF margin-852.8%

Returns & leverage

See full
Return on equity-27.6%-10.2pp
Debt / equity0.0×
Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept MBOT:DeferredTaxAssetsAdvancePaymentFromIia.

The official record: Microbot Medical’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's deferred tax assets advance payment from iia.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Microbot Medical's deferred tax assets advance payment from iia?
Microbot Medical (MBOT) reported deferred tax assets advance payment from iia of $22K in Q4 2025.
What does deferred tax assets advance payment from iia mean?
This metric tracks deferred tax assets associated with advance payments received from government or institutional innovation authorities, such as the IIA. It reflects the tax treatment of non-refundable or conditional grants and funding provided for research and development activities. This is a critical indicator for companies heavily reliant on government-backed R&D funding and the associated tax accounting treatment.